Abercrombie & Fitch Co. (ANF)
NYSE: ANF · Real-Time Price · USD
91.06
-4.96 (-5.17%)
At close: Aug 1, 2025, 4:00 PM
91.15
+0.09 (0.10%)
After-hours: Aug 1, 2025, 7:53 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $123.78, which forecasts a 35.93% increase in the stock price over the next year. The lowest target is $82 and the highest is $210.
Price Target: $123.78 (+35.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 4 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $141 → $151 | Buy | Maintains | $141 → $151 | +65.82% | Jul 28, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $147 → $141 | Buy | Maintains | $147 → $141 | +54.84% | Jun 16, 2025 |
| Raymond James | Raymond James | Buy Maintains $90 → $99 | Buy | Maintains | $90 → $99 | +8.72% | May 29, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $78 → $82 | Hold | Maintains | $78 → $82 | -9.95% | May 29, 2025 |
| Barclays | Barclays | Hold Maintains $71 → $84 | Hold | Maintains | $71 → $84 | -7.75% | May 29, 2025 |
Financial Forecast
Revenue This Year
5.24B
from 4.95B
Increased by 5.93%
Revenue Next Year
5.40B
from 5.24B
Increased by 3.07%
EPS This Year
10.27
from 10.69
Decreased by -3.91%
EPS Next Year
10.80
from 10.27
Increased by 5.15%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.5B | 5.7B | 6.0B |
| Avg | 5.2B | 5.4B | 5.5B |
| Low | 5.0B | 5.2B | 5.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.2% | 9.3% | 10.3% |
| Avg | 5.9% | 3.1% | 2.4% |
| Low | 1.8% | -1.4% | -2.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.97 | 11.92 | 13.49 |
| Avg | 10.27 | 10.80 | 10.90 |
| Low | 9.68 | 8.73 | 7.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.6% | 16.0% | 24.9% |
| Avg | -3.9% | 5.2% | 0.9% |
| Low | -9.4% | -15.0% | -31.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.